NCT01905124View on ClinicalTrials.gov

Safety &Efficacy of CF101 to Subjects With Uveitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2019

Primary Completion Date

September 30, 2019

Study Completion Date

October 31, 2019

Conditions
Uveitis, PosteriorUveitis, Intermediate
Interventions
DRUG

CF101

CF101 1 mg tablets orally every 12 hours for 24 weeks

DRUG

Placebo

Matching placebo tablets orally every 12 hours for 24 weeks

Trial Locations (1)

31048

Bnei-Zion Medical Center, Haifa

Sponsors

Lead Sponsor

Can-Fite BioPharma
All Listed Sponsors
lead

Can-Fite BioPharma

INDUSTRY